Meeting patient expectations in migraine treatment: What are the key endpoints?

Journal of Headache and Pain

Volumn 9, Issue 4, 2008, Pages 207-213

  Antonaci, Fabio ^a   Sances, Grazia ^b   Guaschino, Elena ^b   De Cillis, Ilaria ^b   Bono, Giorgio ^a   Nappi, Giuseppe ^b  

^a Polyclinic of Monza   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Migraine treatment; Outcome; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTIMIGRAINE AGENT; ELETRIPTAN; ERGOTAMINE; NARATRIPTAN; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EARLY INTERVENTION; EXPECTATION; HUMAN; KAPLAN MEIER METHOD; MIGRAINE; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

HUMANS; MIGRAINE DISORDERS; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 49149100467     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-008-0052-8     Document Type: Review

References (25)

1. Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24 Suppl 1:1-160
2. Lipton RB, Stewart WF, Von KM (1997) Burden of migraine: Societal costs and therapeutic opportunities. Neurology 48:S4-S9
3. Lipton RB, Stewart WF, Diamond S et al (2001) Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 41:646-657
4. Mannix LK (2001) Epidemiology and impact of primary headache disorders. Med Clin North Am 85:887-895
5. Von KM, Stewart WF, Simon DJ et al (1998) Migraine and reduced work performance: A population-based diary study. Neurology 50:1741-1745
6. Hu XH, Markson LE, Lipton RB et al (1999) Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159:813-818
7. Lipton RB, Diamond S, Reed M et al (2001) Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 41:638-645
8. Edmeads J (2005) Defining response in migraine: Which endpoints are important? Eur Neurol 53 Suppl 1:22-28
9. Dodick DW, Sandrini G, Williams P (2007) Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21(1):73-82
10. Antonaci F, Chimento P, Diener HC et al (2007) Lessons from placebo effects in migraine treatment. J Headache Pain 8:63-66
11. Foley KA, Cady R, Martin V et al (2005) Treating early versus treating mild: Timing of migraine prescription medicatons among patients with diagnosed migraine. Headache 45(5):538-4511
12. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J (2008) Early vs. non-early intervention in acute migraine 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia (in press)
13. Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans - serotonin 5-HT(1B/1D) agonists - in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358(9294):1668-1675
14. Pascual J (2008) Almotriptan in triptan-naïve patients: New evidence of benefits, Cephalalgia (in press)
15. Dodick Diener HC, Goadsby PJ et al (2008) Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia 28(1):35-40
16. Stewart WF, Lipton RB, Dowson AJ et al. (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56 (6 Suppl 1):S20-S28
17. Brna P, Gordon K, Dooley J et al (2007) Health-related quality of life among Canadians with migraine. J Headache Pain 8(1):43-48
18. Rozen TD, Swanson JD, Stang PE et al (1999) Increasing incidence of medically recognized migraine headache in a United States population. Neurology 53:1468-1473
19. Nappi G, Jensen R, Nappi RE et al (2006) Diaries and calendars for migraine: A review. Cephalalgia 26(8):905-916
20. Hartmaier SL, Santanello NC, Epstein RS et al (1995) Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 35(6):320-329
21. Santanello NC, Hartmaier SL, Epstein RS et al (1995) Validation of a new quality of life questionnaire for acute migraine headache. Headache 35(6):330-337
22. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF36). Med Care 30:473-483
23. Gladstone J, Eross E, Dodick D (2003) Chronic daily headache: A rational approach to a challenging problem. Semin Neurol 23(3):256-276
24. Dowson AJ, Dodick DW, Limroth V (2005) Medication overuse headache in patients with primary headache disorders: Epidemiology, management and pathogenesis. CNS Drugs 19(6):483-497
25. Saper JR (2005) Editorial to the guidelines for trials of behavioral treatments for recurrent headache. Headache 45(Suppl 2):S90-S91